Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415556 · ClinicalTrials.gov registry record · Phase 2
Memory Aid by Intranasal Insulin in Diabetes (MemAID)
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT02415556 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 289 participants.
The verdict
NCT02415556, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
The main purpose of this study is to find the long-term effects of daily administration of 40 IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks with a follow-up period for 24 weeks. Four groups will be tested: DM group treated with INI; DM group treated with placebo; control group treated with INI and the control group treated with placebo. The INI or placebo will be delivered into the nose. The investigators are interested to see whether INI can improve memory and cognition and blood flow in the brain in the type 2 DM group as compared to placebo and to the non-diabetic group over a long-term period.
Interventions
- DRUG Placebo
- DRUG Regular Human Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2015-10-06 |
| Est. Completion | 2020-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02415556
The ClinicalTrials.gov registry entry for NCT02415556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02415556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02415556 about?
NCT02415556 is a clinical study titled "Memory Aid by Intranasal Insulin in Diabetes (MemAID)". The main purpose of this study is to find the long-term effects of daily administration of 40 IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks with a follow-up period f...
What is the current status of trial NCT02415556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2015-10-06. Estimated completion is 2020-05-31.
What interventions are being tested in trial NCT02415556?
The interventions under investigation include: Placebo (DRUG), Regular Human Insulin (DRUG).
Who is sponsoring clinical trial NCT02415556?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.